Afferent Pharmaceuticals Receives $55,000,000 Series C Round

  • Feed Type
  • Date
    7/8/2015
  • Company Name
    Afferent Pharmaceuticals
  • Mailing Address
    2929 Campus Drive San Mateo, CA 94403 USA
  • Company Description
    Develops medicines to treat chronic pain. Afferent Pharmaceuticals is focused on developing first-in-class medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers.
  • Website
    http://www.afferentpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $55,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds will fund the advancement of the company’s first-in-class drug candidate AF-219 for the treatment of pathologic cough, including for cough in IPF patients, as well as advancement of its next candidate compound to the clinic for cardiovascular and other diseases. AF-219 is a selective, non-narcotic and orally administered P2X3 antagonist.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor